Related by context. All words. (Click for frequent words.) 80 Completes Enrollment 80 Completes Patient Enrollment 78 Presents Preclinical Data 78 Present Preclinical Data 78 Presents Positive 77 Publishes 77 Announce Collaboration 77 Initiates Phase II 76 Announces Initiation 76 Reports Positive 76 Announces Presentation 76 Receives Patent 76 Announce License Agreement 75 Initiates Clinical Trial 75 Files IND 75 Announces Positive 75 Initiates Phase 75 Receives Milestone Payment 75 Announces Successful Completion 75 Awarded Patent 75 Sign License Agreement 75 Files Patent Application 75 Shows Promise 74 Receives Positive 74 Initiates Clinical Trials 74 Receives Orphan Drug Designation 74 Announces FDA Clearance 74 Announces Licensing Agreement 74 Announces Availability 74 Receives Favorable 74 Provides Guidance 74 Announces Termination 74 Provides Update Regarding 74 Demonstrates Significant 74 Announce Collaboration Agreement 74 Announces License Agreement 74 Receives FDA Clearance 74 Initiates Dosing 74 Announces Receipt 74 Announces Formation 74 Enter Into 74 Drug Candidate 74 Submits NDA 74 Announces Completion 73 Clinical Trial Results 73 Collaborators Present 73 Presents Preclinical 73 FDA Clears 73 Receives Approvable Letter 73 Obtains Approval 73 Significantly Reduces 73 Successfully Completes Phase 73 Announces Launch 73 Enrolls First 73 Receives NASDAQ 73 Commences Phase 73 Announces Issuance 73 Submits Application 73 Initiates Phase III 73 Reveals Positive 73 Announces Stockholder Approval 73 Signs Licensing Agreement 72 Initiates Clinical 72 Study Confirms 72 Preclinical Data 72 Expand Collaboration 72 Updates Status 72 Initiates Enrollment 72 Signs Agreements 72 Announces Commencement 72 Reports Preclinical Data 72 Significantly Increases 72 Sign Licensing Agreement 72 Provides Comprehensive 72 Strengthens Its 72 Jointly Announce 72 Host Webinar 72 Launches Next Generation 72 Announce Licensing Agreement 72 Reconfirms 72 Collaborators Publish 72 Announces Favorable 72 Announce Initiation 72 Significantly Improves 72 Receives Notification 72 Report Indicates 72 Announces Preliminary 72 Improves Survival 72 Meets Primary Endpoint 71 Attains 71 Announce Completion 71 Patent Issued 71 Files Patent 71 Study Identifies 71 Announces Poster Presentations 71 Successfully Completes 71 Announces Addition 71 Identifies Potential 71 Investigational Compound 71 Enters Agreement 71 Discontinues 71 Jumps Higher 71 Successfully Concludes 71 Provides Updates 71 Announces Postponement 71 Completes Merger With 71 Receives Notice 71 Study Indicates 71 Introduces Next Generation 71 Announces Immediate Availability 71 Board Authorizes 71 Announces Successful 71 Revolutionizes 71 Confirms Receipt 71 Closes Sale 71 Receives Orphan Drug 71 Announces Filing 71 Achieves Milestone 71 Updates Shareholders 71 Files Shelf Registration Statement 71 Announces Signing 71 Complete Merger 71 Finalizes Acquisition 71 Completes Merger 71 Reduces Risk 71 Submits 71 Announces Cancellation 71 Host Webcast 71 Preclinical Study 71 FDA Approves 71 Validates 71 Study Proves 71 Successful Completion 71 Significantly Expands 70 Expand Relationship 70 Announces Appointment 70 Licenses Novel 70 Unveils Latest 70 Report Examines 70 Announce Merger Agreement 70 Summarizes 70 Introduces Breakthrough 70 Announces Expanded 70 Successfully Completed 70 Explore Strategic Alternatives 70 Announces Effective Date 70 Discloses 70 FDA Accepts 70 Elevates 70 Positive Results 70 Announce Agreement 70 Presents Positive Preclinical 70 Signs License Agreement 70 Provides Preliminary 70 Secures Financing 70 Furthers 70 Present Webinar 70 Announce Availability 70 Announces Revised 70 Launches Innovative 70 Finalizes 70 Announces Shareholder Approval 70 Study Demonstrates 70 Fortifies 70 Announces 70 Regains Compliance With 70 Provides Update 70 Initiates Phase 2b 70 Launches Unique 70 Regains Compliance 70 Cites Positive 70 Therapeutic Competitors Companies 70 Launches Enhanced 70 Inhibits 70 Announces Departure 70 Commences Tender Offer 70 Sinks Lower 70 Statement Regarding 70 Receives SFDA Approval 70 Commercializes 70 Results Confirm 69 Provides Detailed 69 Net Loss Narrows 69 FDA Okays 69 Issues Statement Regarding 69 Secures Funding 69 Phase 2b Clinical Trial 69 Demonstrates Positive 69 Submits IND 69 Announces Enhancements 69 Amends Agreement 69 Announces Resignation 69 Issues Guidance 69 Completes Initial 69 Completes Successful 69 Provides Updated 69 Expands Portfolio 69 Enters Into Agreement 69 Announces Additions 69 Shareholders Approve Merger 69 Further Strengthens 69 Confirms Commitment 69 News Unternehmensnachrichten 69 Collaborates With 69 Provides Clarification 69 Wins Approval 69 Begins Dosing 69 Extends Collaboration 69 Announces Acquisition 69 Receives Unsolicited 69 Completes Acquisition 69 Receives Notice From 69 Completes 69 Strengthens Position 69 Develops Novel 69 Gets FDA Clearance 69 Introduces Revolutionary 69 Prolongs Survival 69 Proudly Announces 69 Q3 Loss Narrows 69 Launches 69 Reaffirms Commitment 69 DOR BioPharma Announces 69 Announces Upcoming 69 Settles Litigation 69 Issues Statement 69 Reveals 69 Exercises Option 69 Spectrum Pharmaceuticals Announces 69 Evaluate Strategic Alternatives 69 Develop Novel 69 Closes Acquisition 69 Announces Dismissal 69 Drug Shows Promise 69 Announce Receipt 69 Seeks Approval 69 Induces 69 Announce Partnership 69 Files Amended 69 Releases Latest 69 Completes Divestiture 69 Formalizes 69 Q2 Loss Narrows 69 Receives Fast Track 69 Finalizes Agreement 69 Releases Next Generation 69 Receives Certification 69 Subsidiary Signs 69 Introduces Innovative 69 Shows Promising 69 Unveils Innovative 69 Announce Settlement 69 Introduces 69 Launches Redesigned Website 69 Q2 Loss Widens 69 More Than Doubles 69 Unveils Next Generation 69 Begins Shipment 69 Improves Outcomes 69 Q3 Loss Widens 69 Completes Acquisitions 68 Platform Enables 68 Announce Definitive Agreement 68 Demonstrates Potential 68 Expands Scientific Advisory 68 Announces Proposed 68 Novel Oral 68 Therapeutic Competitors companiesandmarkets.com adEgemonye 68 Study Shows Benefits 68 Completes Transaction 68 Restructures Operations 68 Elects 68 Receives Approval 68 Expands Capabilities 68 Announce Strategic 68 Consummates 68 Significant Increase 68 Appoints 68 Files Registration Statement 68 Progresses 68 Successfully Completes Tender Offer 68 Awarded Patents 68 Acquires Assets 68 Receives Favorable Ruling 68 Holds Promise 68 Announces Webcast 68 Phase 2b Trial 68 Magazine Recognizes 68 Stockholders Approve 68 Completes Tender Offer 68 Receives Clearance 68 Changes Name 68 Effectively Treats 68 Initiates 68 BioSante Pharmaceuticals Announces 68 Receives Notice Regarding 68 Announce Commencement 68 Enters Into 68 Phase IIb Clinical Trial 68 Files Investigational 68 Patent Covering 68 Refocuses 68 Phase III Clinical Trial 68 Retracts 68 Net Loss Widens 68 Extends Reach 68 Spins Out 68 Completes Purchase 68 Continues Momentum 68 Emphasizes Importance 68 Shareholders Approve 68 Ranked Number 68 Subsidiary Enters 68 Quadruples 68 Submits Biologics License Application 68 Spins Off 68 Introduces Enhanced 68 Patient Enrollment 68 Sends Letter 68 Announces Divestiture 68 Acquire Assets 68 Broadens Its 68 Extend Collaboration 68 Completes Transition 68 Launches Groundbreaking 68 Pending Acquisition 68 Study Validates 68 Increases Risk 68 Granted Orphan Drug 68 Celebrates Successful 68 Unveils 68 Immunomedics Announces 68 Completes Sale 68 Announces Intent 68 Planned Acquisition 68 Nears Completion 68 Continues Aggressive 68 Strengthens Leadership 68 Proves Successful 68 Enters Into Strategic 68 Helps Reduce 68 Announce Formation 68 Study Examines 68 Phase III Trial 68 Acquires Exclusive 68 Q4 Loss Narrows 68 Receives Commitment 68 Q1 Loss Narrows 68 Reports Significantly Improved 68 Unveils Expanded 68 Q4 Loss Widens 68 Announces Adjournment 67 Achieves Significant 67 Outperforms 67 Enters Into Exclusive 67 Receives Confirmation 67 Completes Previously Announced 67 Significantly Improve 67 Officially Launches 67 Shareholders Approve Acquisition 67 Anounces 67 Regains NASDAQ 67 Signs Option Agreement 67 Voluntarily Withdraw 67 Flamel Technologies Announces 67 Announce Exclusive 67 Therapeutic Antibody 67 Reports Receipt 67 Posts Strong 67 Repositions 67 Q1 Loss Widens 67 Announces Expansion 67 Receives Prestigious Award 67 Announces Organizational Changes 67 Sharpens Focus 67 Announces Expiration 67 Settle Patent Litigation 67 Announcement Regarding 67 Confirms Filing 67 Delivers Unprecedented 67 Expands Scope 67 CybeRelease Decliners 67 Updates Guidance 67 Reinforces 67 Announces Redemption 67 Acquire Controlling Interest 67 Announce Expiration 67 Website Launched 67 Jointly Develop 67 Receives Regulatory 67 Previously Treated 67 Announce Signing 67 Stockholders Approve Merger 67 Streamlines Operations 67 Extends Tender Offer 67 Temporarily Suspends 67 Proven Effective 67 Introduces Novel 67 Initiate Phase III 67 Dramatically Improves 67 Commences 67 Completes Patient Enrolment 67 Successful Outcome 67 BIOLASE Announces 67 Study Sheds Light 67 CRWESelect CRWESelect.com Highlights 67 Identifies Key 67 Secures Additional 67 Therapy Improves 67 Finalizes Purchase 67 Latest Addition 67 Subsidiary Acquires 67 Receives Conditional Approval 67 Obtains Exclusive License 67 Outlines Strategy 67 Annouces 67 Broadens 67 Oral Calcitonin 67 Clinical Trial Evaluating 67 Transdermal Patch 67 Dramatically Increases 67 Debuts 67 Enters Into License Agreement 67 Provides Shareholder 67 Wins Prestigious 67 Delivers Strong 67 Extends Expiration Date 67 &Amp; 67 Small Molecule 67 Reminds Shareholders 67 Anti Tumor 67 Amplifies 67 Earns Milestone Payment 67 Stockholders Approve Acquisition 67 Ink Deal 67 Vaccine Adjuvant 67 Acquires Controlling Interest 67 Accepted Into 67 Strengthens Balance Sheet 67 Obtains 67 Board Unanimously Rejects 67 Completes Financing 67 Appoints Seasoned 67 Completes Recapitalization 67 Study Evaluating 67 Antitumor Activity 67 Announces Discontinuation 67 Issues Clarification 67 Declares Increase 67 Phase IIa Clinical Trial 67 Protects Against 67 Receives Complete Response 67 Restate Financial 67 Announce Early Termination 67 Shares Soar 67 Relationship Between 67 Systemic Delivery 67 Reacquires 67 Maintains Strong 67 Inc Therapeutic Competitors 67 Previously Announced 67 Announce Merger 67 Signs Agreement 67 Researchers Identify 67 Lupus Drug 67 Forges Ahead 67 Buys Majority Stake 67 Introduces Powerful 67 Gets Approval 67 Releases Findings 66 Receives Prestigious 66 Obtains License 66 Achieves Record Sales 66 Proves Effective 66 Completes Sale Of 66 Achieves Positive 66 Launches Website 66 Provides Insights 66 Acquirer Company 66 Files Definitive Proxy 66 Innovative Approach 66 Secures Patent 66 Reduces Debt 66 Correlation Between 66 Subsidiary Receives 66 Receives Recognition 66 Releases Enhanced 66 Develop Next Generation 66 Initiates Voluntary Recall 66 Announce Successful Completion 66 Receives Conditional 66 Secures Long Term 66 Patents Covering 66 Finalises 66 Appoints Experienced 66 Lowers Risk 66 Announces Definitive Agreement 66 Re Affirms 66 Adopts Shareholder Rights 66 Hsp# Inhibitor 66 Welcomes Analyst Initiation 66 Milestone Achieved 66 Receives CE Marking 66 Achieves Record 66 Taglich Brothers Initiates Coverage 66 AUDIO PROVIDED BY 66 Refines 66 Rated Speculative Buy 66 Moves Forward 66 Directors Authorizes 66 Builds Momentum 66 Concludes Successful 66 Announces Tentative Approval 66 Study Reveals 66 Initiate Phase 66 Files Annual Report 66 Extends Relationship 66 Gains Momentum 66 Monetizes 66 Inc. Nasdaq OXGN 66 Study Showed 66 Announces Intention 66 Deliver Presentation 66 Data Suggest 66 Clarifies Status 66 Unifies 66 Develop Innovative 66 Begins Shipping 66 Develops Innovative 66 Announces Tender Offer 66 Submits Response 66 Inflammatory Arthritis 66 IND Application 66 Shows Promise Against 66 TriCo Bancshares Announces 66 Report Analyzes 66 Sees Continued 66 Sees Strong 66 JAK2 Inhibitor 66 Relaunches 66 Accelerates 66 Terminates Contract 66 Announces Closing 66 Redefines 66 Scientists Uncover 66 Orally Active 66 Successfully Complete 66 Shares Surge 66 Confirms 66 Introduces Expanded 66 Celebrates Decade 66 Inks Deal With 66 Voluntarily Withdraws 66 Migraine Drug 66 Directors Elects 66 Provide Comprehensive 66 Strongly Supports 66 Treating Chronic 66 Achieves Profitability 66 Unveils Revolutionary 66 Delays Filing 66 Phase 2a Trial 66 #-# Full Text 66 Engages 66 Diagnostic Tests 66 Announces Sponsorship 66 PPD Declares 66 Low Dose 66 Report companiesandmarkets.com adds 66 Drug Fails 66 Newly Released 66 Enters Joint Venture 66 Differences Between 66 Substantially Increases 66 Protease Inhibitor 66 IrelandRESEARCH AND MARKETS 66 JAK Inhibitor 66 Enters Into Agreements 66 Bolsters 66 Joins OTCQX 66 Revitalizes 66 Hosts Webinar 66 Enters Into Definitive Agreement 66 Files Lawsuit Against 66 Announce Licensing 66 Suppresses 66 Further Validates 66 Unveils Newest 66 Regains Full 66 Well Tolerated 66 Reaches Milestone 66 Confirms Significant 66 Expert Joins 66 Study Shows 66 CONFERENCE CALLS SOURCE 66 Wins Coveted 66 Joins 66 Delivers Next Generation 66 Commercialize 66 Increases Size 66 Announces Resumption 66 Completes Reorganization 66 Epilepsy Drug 66 Demystifies 66 Enters Into Definitive 66 Tyrosine Kinase Inhibitor 66 Study Suggests 66 Helps Identify 66 Posts Wider Loss 66 Receives Approval From 66 Receives Accolades 66 Completes Private Placement 66 Terminates Agreement 66 Reorganizes 66 Achieves Highest 66 Closes Acquisition Of 66 Single Dose 66 Increases Stake 66 Gains Ground 66 Combination Treatment 66 ISS Recommends 66 Receives Subpoena 66 Accelerates Growth 66 Could Revolutionize 66 Restructures 66 Bush Embraces Pause 66 CFO Resigns 65 Commercialize Novel 65 Closes Merger 65 Evolves 65 Announce Expanded 65 Files Shelf Registration 65 Anti Tumor Activity 65 Files Preliminary Proxy 65 First Patient Enrolled 65 Licenses Patents 65 Presents Webinar 65 Realigns 65 Sheds Light 65 Stock Soars 65 Unveils Breakthrough 65 Announce Joint Venture 65 Distinguishes 65 Stays Neutral 65 Discovers 65 Abstract Accepted 65 Obtains Patent 65 Announces Dates 65 Releases 65 Bone Metastases 65 Deepens 65 FDA Approvals 65 Novel Antibiotic 65 Successfully Closes 65 Prescribes 65 REPLACING 65 Ranks Number 65 Novartis Novo Nordisk 65 Congratulates 65 Tumor Targeting 65 Conference Call TRANSCRIPT 65 Alert Technicals Showing Bearish 65 Statistically Significant 65 Initiate Clinical Trial 65 Achieves Primary Endpoint 65 Reach Settlement Agreement 65 Launches Breakthrough 65 Plays Role 65 Retains Leading 65 Unveils Enhanced 65 Signs Contract 65 Releases Podcast 65 Reaches Agreement 65 Receives Funding 65 Completes Redemption 65 Meta Analysis 65 Announces Effectiveness 65 Receives 65 Posts Higher 65 Announces Affiliation 65 Demonstrates Commitment 65 Expert Discusses 65 Unveils Groundbreaking 65 Completes Installation 65 Remains Committed 65 Survival Benefit 65 Emphasizes Need 65 Commence Phase 65 Ink Pact 65 Announces Restatement 65 PRODUCT SOURCE 65 Webcast Presentations 65 Reports Profitable 65 Awarded Prestigious 65 Trend Continues Down 65 Being Evaluated 65 Withdraws Proposal 65 Momentum Continues 65 Restructures Debt 65 Ramps Up 65 Successfully Completes Acquisition 65 Finalizes Sale 65 Clears Path 65 DayTradersDigest.com Profiles 65 Increased Risk 65 Posts Record 65 Announces Pricing 65 Enters Into Joint Venture 65 Osteoporosis Drug 65 Remains Neutral 65 Terminates 65 Acquires 65 Receives Accreditation 65 Shows Efficacy 65 Releases Third Quarter 65 Settle Patent Dispute 65 Closes Second Tranche 65 Therapeutic Potential 65 Phase IIb Trial 65 Shown Effective 65 Announces Participation 65 Closes Previously Announced 65 Receive Milestone Payment 65 Makes Strides 65 Helps Prevent 65 Holds Annual Meeting 65 Randomized Trials 65 Unleashes 65 Reinvents 65 Helps Predict 65 Cuts Costs 65 Helps Ensure 65 Receive Prestigious 65 Closes Buyout 65 Delay Filing 65 Kinase Inhibitor 65 Reveals Secrets 65 Commences Phase III 65 Increases Ownership 65 Rebrands 65 Test Detects 65 Leading Provider 65 Underscores Importance 65 Acquisition Strengthens 65 Non Invasive 65 Adjunctive Therapy 65 Subtypes 65 Approve Merger 65 Achieves ISO #:# Certification [002] 65 Solidifies 65 Extends Offer 65 Mouse Model 65 Q2 Profit Rises 65 Uncovers 65 Updates Outlooks 65 Bullish Average Crossover 65 Trial Evaluating 65 Report Identifies 65 Attracting Bullish Investors 65 Systematic Review 65 Increases Efficiency 65 Seek Shareholder Approval 65 Key Milestones 65 Commends 65 Receives Tentative Approval 65 FDA Warns 65 Publishes Updated 65 Inks Pact 65 Signs Merger Agreement 65 Buy Privately Held 65 Given Outperform Rating 65 Strengthens Commitment 65 Significantly Improved 65 Unlocks 65 Snaps Up 65 Reveals Receipt 65 Completes Buyout 65 Holds Annual 65 Molecular Mechanism 65 Executes Agreement 65 Nominates 65 Clinical Outcome 65 L.P. Announces 65 Announces Stock Repurchase 65 Expands 65 Phase 1b Clinical Trial 65 Shareholders Elect 65 Receives Endorsement 65 Directors Unanimously Rejects 65 Thewallstreetleader.com Profiles 65 Responds 65 Aethlon Medical Releases 65 Adopts 65 Improves Quality 65 Webcast Annual Meeting 65 Speeds Up 65 Completes Expansion 65 Expands Capacity 65 Achieves Certification 65 Positions Itself 65 Resubmits 65 Report Cites 65 Marks Milestone 65 Authorizes Additional 65 Guides Below 65 Completes Reverse Merger 65 Signs Definitive Agreement 65 Beneficial Effects 65 Affirms Commitment 65 Univest Corporation Declares 65 Redeems 65 Forms Strategic 65 Succeeds 65 Lung Cancer Drug 65 Plummets 65 Adopts Stockholder Rights 65 Patients Enrolled 65 Report Suggests 65 Arthritis Drug 65 Successfully Tests 65 Report Reveals 65 Commences Trading 65 Reduce Risk 65 Confirms Efficacy 65 Completes Integration 65 Significantly Enhances 65 Sets Dates 65 Achieves Unprecedented 65 Significant Improvement 65 Shares Plummet 65 Be Discussed 65 Diversifies 65 Accepts Resignation 65 Paves Way 65 Looks Promising 64 Study Concludes 64 Pharmacyclics Announces 64 Sangamo BioSciences Announces 64 Boosts Productivity 64 Expands Reach 64 Technicals Showing Bullish 64 Reschedules 64 Announces Share Repurchase 64 PROFILE CO 64 Receives Positive Opinion 64 TSX Delisting 64 Appears Safe 64 Shines Spotlight 64 Sees Significant 64 Announces Rebranding 64 Sets Record Date 64 Study Analyzes 64 Confirmatory Phase 64 Host Fourth Quarter 64 Subscribes 64 Results Indicate 64 Moves Into 64 Signs MOU 64 Completes Conversion 64 Sees Continued Growth 64 Being Studied 64 First Patient Treated 64 Combination Therapy 64 Zacks Analyst Blog Highlights 64 Winning Streak Continues 64 Pharmaceuticals Initiates 64 Rolls Out 64 Signs Memorandum 64 Renews Agreement 64 Lowers Guidance 64 Could Prevent 64 Demonstrates Statistically Significant 64 Sees Positive 64 Sets Record 64 Gains Traction 64 Unveils Powerful 64 Outlines Vision 64 Debuts Next Generation 64 Delivers Breakthrough 64 Proposes Merger 64 Markettelegraph.com 64 Nicotine Vaccine 64 Renews Commitment 64 Completes Purchase Of 64 Refutes 64 Expands Presence 64 Unwraps 64 Patients Treated 64 Disappoints 64 Initiates Coverage 64 Aquires 64 Endorses 64 Restates 64 Closes Financing 64 Finalize Agreement 64 Controlled Trial 64 Pivotal Study 64 Mylan Receives Approval 64 Announces Early Termination 64 Announces Mailing 64 Signs Exclusive 64 Enters Strategic 64 Rapidly Growing 64 Q4 Profit Surges 64 Announce 64 R MSCRAMM 64 Investigational Drug 64 Review Strategic Alternatives 64 Improves Efficiency 64 Patients Treated With 64 Oncology Compounds 64 Upcoming Conferences 64 Scientists Identify 64 Declares Quarterly Dividends 64 Taro Receives 64 Profitable Quarter 64 Chronic Hepatitis C 64 Takes Delivery 64 Reaffirms 64 Applauds 64 Announce Interoperability 64 Enlarges 64 Awarded Contracts 64 Step Toward 64 RNAi Therapeutic 64 Vascular Inflammation 64 Combination REOLYSIN R 64 Stands Out 64 Inks MOU 64 Expands Commitment 64 Named Finalist 64 Posts Narrower Loss 64 OTCStockExchange.com Stock Alert 64 Provides Unprecedented 64 Report Initiates Independent 64 Coverage Initiated 64 Expands Relationship 64 Sets Date 64 BIOTECHNOLOGY SOURCE 64 Lanthanum Carbonate 64 Announces Consummation 64 Wins Contract 64 Settles Dispute 64 Earns Recognition 64 Milestone Reached 64 Pursues 64 Introduces Unique 64 Files Preliminary Prospectus 64 Inhaled Liposomal Ciprofloxacin 64 Announces Private Placement 64 Q2 Profit Declines 64 Wins Prestigious Award 64 Announces Favorable Ruling 64 Webcast Second Quarter 64 Declares Increased 64 Other OTC MNDP 64 HCV Protease Inhibitor 64 Study Links 64 Promotes 64 Leadership Position 64 Joins Forces 64 Moves Closer 64 Continues Expansion 64 Moves Ahead 64 Settle Litigation 64 Signs Joint Venture 64 Protein Synthesis 64 Announces Retirement 64 Extends Leadership 64 Revises Fourth Quarter 64 Volume Spikes 64 Markets Examine 64 Patients Undergoing 64 Cell Transplants 64 Unsolicited Proposal From 64 Delivers Powerful 64 RNAi Therapeutics 64 Q1 Adj 64 Bodes Well 64 Expands Coverage 64 Delivers Solid 64 Attracts Attention 64 Shines Light 64 Pooled Analysis 64 4Q Loss Widens 64 Has Received 64 BayStreet.ca Research Alert 64 Prolongs 64 Announces Recapitalization 64 Novel Method 64 Signs Pact 64 Demonstrates 64 Enters Into Licensing Agreement 64 Commences Consent Solicitation 64 Files Revised 64 Has Re Crossed 64 Offers Unique 64 Could Trigger 64 SWOT Analysis Aarkstore Enterprise